Lipid-lowering drug therapies: the evidence
نویسندگان
چکیده
منابع مشابه
Lipid-lowering drug therapies: the evidence.
Abbreviations: CARE, Cholesterol and Recurrent Events; LIPID, Long-term Intervention with Pravastatin in Ischaemic Disease. Corresponding author: Professor Chris Packard, fax +44 (0)141 211 4322, email [email protected] CAB InternationalPNSProceedings of the Nutrition Society (2000)0029-6651© Nutrition Society 2000 593 59423Cardiovascular disease risk: lifestyle v. drugsC. Packard423 ...
متن کاملLipid-lowering drug therapies and chronic obstructive pulmonary disease: lung failure or just heart failure?
Lipids are intimately involved in metabolism in the lung. Lipid-lowering drugs, primarily statins, are prescribed for patients both with established and with developing cardiovascular disease (CVD) (1). Statins improve microvascular and endothelial function (1,2). As statins inhibit early in the pathway of cholesterol synthesis, they also reduce isoprenoid intermediates involved in the control ...
متن کاملPrimary prevention lipid-lowering drug therapy.
To the Editor: We appreciate the editorial comments provided by Drs Gotto and Kuller1 on our article published in the January 15, 2002, issue of Circulation,2 but we wish to respond to several issues raised. The methodology used to project population size is standard for the Third National Health and Nutrition Examination Survey (NHANES III) and is described thoroughly in the publication by the...
متن کاملOvercoming toxicity and side-effects of lipid-lowering therapies.
Lowering serum lipid levels is part of the foundation of treating and preventing clinically significant cardiovascular disease. Recently, the American Heart Association/American College of Cardiology released cholesterol guidelines which advocate for high efficacy statins rather than LDL-c goals for five patient subgroups at high risk for cardiovascular disease. Therefore, it is critical that c...
متن کاملGlycaemic Effects of Non-statin Lipid-Lowering Therapies
Since the publication of the JUPITER trial, attention has been focused on the adverse glycemic effects of statin therapy. Although the modest increase in the risk of new diabetes mellitus is outweighed by the reduction in cardiovascular events for statins, emerging biochemical and genetic links between lipid metabolism and glycemic control raise the prospect of a broader diabetogenic effect of ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Proceedings of the Nutrition Society
سال: 2000
ISSN: 0029-6651,1475-2719
DOI: 10.1017/s0029665100000513